Robin/openwiki-wiki
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

chore: daily update 2026-07-30

Browse Source
This commit is contained in:
OpenWiki Bot
2026-07-30 02:13:32 +08:00
parent 61b7c0858b
commit e7d4f64e85
7 changed files with 173 additions and 31 deletions
Download Patch File Download Diff File Expand all files Collapse all files
commitments.md
+14
View File
@@ -25,6 +25,20 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G
- Status: open
- Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.
### cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check
- Owner: me
- Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing `celvivo-clinoreactor-thewell-bioscience-xeno-free` item.
### china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning
- Owner: me
- Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
- Due: unscheduled
- Status: open
- Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.
<!--
Structure for new entries: